Tung T Wynn

Tung T Wynn, M.D.

Clinical Associate Professor

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9120
Business Email: twynn@ufl.edu

About Tung T Wynn

Tung Wynn, M.D., attended Northeastern Ohio Medical University for medical school and stayed at Children’s Hospital Medical Center of Akron to complete his pediatric residency. He then completed his fellowship in Pediatric Hematology/Oncology at Ohio State University and Nationwide Children’s Hospital. Dr. Wynn became an attending physician in Pediatric Hematology/Oncology at St. Joseph’s Children’s Hospital of Tampa in 2003. He joined the University of Florida faculty in 2012 as an assistant professor in the division of Pediatric Hematology/Oncology. He is also the director of the UF Pediatric Hemostasis Program and the UF Pediatric Cancer Survivorship Program. Dr. Wynn currently holds professional memberships with the American Society of Hematology, Florida Medical Association, Children’s Oncology Group, American Society of Clinical Oncology, American Society of Pediatric Hematology/Oncology and the American Academy of Pediatrics.

Teaching Profile

Courses Taught
2018
MDC7400 Pediatric Clerkship
2018
MDT7400 Elect Top/Pediatrics
2018
MDC7401 Senior Pediatric Clk

Board Certifications

  • Pediatric Hematology-Oncology
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Hemophilia

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-7331-4364

Publications

2022
Multidisciplinary Management of a Hemophilia A Patient Requiring Coronary Artery Bypass Graft Surgery
Journal of Cardiothoracic and Vascular Anesthesia. 36(2):534-538 [DOI] 10.1053/j.jvca.2021.10.029.
2021
Preclinical development of plant-based oral immune modulatory therapy for haemophilia B.
Plant biotechnology journal. 19(10):1952-1966 [DOI] 10.1111/pbi.13608. [PMID] 33949086.
2020
Bivalirudin and Alteplase for Pulmonary Embolism Requiring Veno-Arterial Extracorporeal Membrane Oxygenation in an Adolescent.
The journal of extra-corporeal technology. 52(4):327-331 [DOI] 10.1182/ject-2000013. [PMID] 33343036.
2020
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
Clinical pharmacokinetics. 59(2):245-256 [DOI] 10.1007/s40262-019-00809-6. [PMID] 31435896.
2020
Primary pulmonary artery sarcoma in the pediatric patient: Review of literature and a case report.
Radiology case reports. 15(7):1110-1114 [DOI] 10.1016/j.radcr.2020.05.016. [PMID] 32477441.
2019
Hemophilia Gene Therapy: New Development from Bench to Bed Side.
Current gene therapy. 19(4):264-273 [DOI] 10.2174/1566523219666190924121836. [PMID] 31549954.
2019
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Haemophilia : the official journal of the World Federation of Hemophilia. 25(5):773-781 [DOI] 10.1111/hae.13807. [PMID] 31353761.
2018
Late Effects After Radiotherapy for Childhood Low-grade Glioma.
American journal of clinical oncology. 41(3):307-312 [DOI] 10.1097/COC.0000000000000267. [PMID] 26808258.
2016
Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Haemophilia : the official journal of the World Federation of Hemophilia. 22(4):e251-8 [DOI] 10.1111/hae.12963. [PMID] 27328112.
2016
Potential role of a new PEGylated recombinant factor VIII for hemophilia A.
Journal of blood medicine. 7:121-8 [DOI] 10.2147/JBM.S82457. [PMID] 27382347.
2015
Results of a Pivotal Clinical Trial Evaluating a Full-Length Pegylated Recombinant Factor Viii (Peg-Rfviii) With Extended Half-Life in Haemophilia a
. 21(2, SI):30-31
2015
Results of a Pivotal Clinical Trial Evaluating a Full-Length Pegylated Recombinant Factor Viii (Peg-Rfviii) With Extended Half-Life in Hemophilia a
. 21(3)
2015
Results of a Pivotal Clinical Trial Evaluating a Full-Length Pegylated Recombinant Factor Viii (Peg-Rfviii) With Extended Half-Life in Hemophilia a
. 21(3)
2014
Late toxicity following craniospinal radiation for early-stage medulloblastoma.
Acta oncologica (Stockholm, Sweden). 53(4):471-80 [DOI] 10.3109/0284186X.2013.862596. [PMID] 24564687.
2012
The Need for Gene Therapy for the Effective Treatment of Hemophilia.
Journal of genetic syndromes & gene therapy. Suppl 1 [PMID] 25309817.
2003
Acute lymphoblastic leukemia with hypereosinophilia: report of a case with 5q deletion and review of the literature.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 6(6):558-63 [PMID] 15018456.
2003
Prenatal presentation supports the in utero development of congenital leukemia: a case report.
Journal of pediatric hematology/oncology. 25(2):148-52 [PMID] 12571468.

Grants

Jun 2022 ACTIVE
Hemophilia Treatment Centers (SPRANS)
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
May 2022 ACTIVE
Upper Extremity Exercise to Improve Vascular Volume, Ease of IV Infusions, Factor Compliance, and Quality of Life in Patients with Hemophilia
Role: Other
Funding: NATL HEMOPHILIA FOU
Apr 2022 ACTIVE
ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Malignant/Non-Neoplastic Hematologic Disorders
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Apr 2022 ACTIVE
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
Role: Other
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Nov 2021 ACTIVE
Gene-transfer, open-label, dose-escalation study of SPK-8011 [adeno-associated viral vector with B-domain deleted human factor VIII gene] in individuals with hemophilia A
Role: Principal Investigator
Funding: PSI CRO via SPARK THERAPEUTICS
Nov 2021 ACTIVE
A Phase 3 Open-Label, Multicenter Study of the Long-Term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients with Severe Hemophilia A.
Role: Principal Investigator
Funding: SANOFI
Sep 2021 ACTIVE
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2021 ACTIVE
ATHN Data Quality Counts (DQC) Program – Round 13
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Jun 2021 ACTIVE
Phase 3 open-label, multicenter study of the safety, efficacy and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV001) in previously treated pediatric patients <12 years of age with severe hemophilia A
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via SANOFI
Jun 2021 ACTIVE
A Phase 3b, multi-center, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension phase to evaluate the efficacy and safety of Avatrombopag for the treatment of thrombocytopenia in pediatric patients with immune thrombocytopenia (ITP) for =6 months.
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via DOVA PHARMACEUTICALS
Jun 2021 – May 2022
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program.
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Sep 2020 – Sep 2021
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020 – Aug 2021
ATHN Data Quality Counts (DQC) Award Round 12
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Jun 2020 ACTIVE
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONGTERM SAFETY AND EFFICACY OF rVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD)
Role: Principal Investigator
Funding: IQVIA via BAXALTA US
Jun 2020 – May 2021
Hemophilia Treatment Centers (SPRANS) Southeast Region Maternal and Child Health Bureau (MCHB) Bleeding Disorders Program
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Feb 2020 ACTIVE
A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc von Willebrand Factor XTEN Fusion Protein (rFVIIIFc VWF XTEN; BIVV001) in Previously Treated Patients =12 Years of Age With Severe Hemophilia A
Role: Principal Investigator
Funding: PSI CRO via BIOVERATIV THERAPEUTICS
Nov 2019 ACTIVE
A Phase 3, Randomized, OpenLabel, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
Role: Principal Investigator
Funding: AMAG PHARMACEUTICALS INC via ICON CLINICAL RESEARCH INC
Sep 2019 – Sep 2020
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2019 ACTIVE
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Aug 2019 – Jun 2022
DISPLACE: Dissemination and Implementation of Stoke Prevention looking at the Care Environment
Role: Principal Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM via NATL INST OF HLTH NHLBI
Jun 2019 – May 2020
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program.
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Mar 2019 – Feb 2022
A prospective study in subjects with severe Hemophilia A who are currently receiving a marketed FVIII therapy.
Role: Principal Investigator
Funding: PSI CRO via BIOVERATIV THERAPEUTICS
Feb 2019 ACTIVE
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Feb 2019 – Jun 2021
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Coagulation Replacement Factor Products
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Jan 2019 ACTIVE
A Multi-Center Observational Study in Males with Hemophilia A
Role: Principal Investigator
Funding: SYNEOS HEALTH via SPARK THERAPEUTICS
Sep 2018 – Sep 2020
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders Project.
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2018 – Aug 2021
A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via GENENTECH INC
Jul 2018 – Aug 2020
ATHN Data Quality Counts 10
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Jun 2018 – May 2019
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
May 2018 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Mar 2018 – Jan 2022
Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice
Role: Principal Investigator
Funding: Octapharma USA
Sep 2017 – Sep 2018
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2017 – Aug 2022
Understanding Hemophilia A and b Drug Dosage Administration Patterns
Role: Principal Investigator
Funding: KANTAR HLTH via PFIZER INC
Jun 2017 – May 2018
7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis
Role: Principal Investigator
Funding: BAYER HEALTHCARE
Jun 2017 – May 2018
Southeast Region Maternal and Child Health Bureau Bleeding Disorders Program
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Mar 2017 ACTIVE
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Role: Principal Investigator
Funding: IQVIA via BAXALTA INNOVATIONS GMBH
Feb 2017 – Feb 2020
A Multinational Phase IV Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Role: Principal Investigator
Funding: BAYER HEALTHCARE
Feb 2017 – Jun 2021
Evaluation of Joint Arthropathy Using Ultrasound Techniqque in Children with Severe Hemophilia Undergoing Prophylaxis Regimen: The Hemophilia Ultrasound Project (HUP Study)
Role: Principal Investigator
Funding: UNIV OF MIAMI via BAXALTA US
Feb 2017 – Dec 2018
My Life, Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository
Role: Principal Investigator
Funding: AMER THROMBOSIS AND HEMOSTASIS NETWORK
Sep 2016 – Sep 2017
Community Counts Public Health Surveillance for Bleeding Disorders Project
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2016 – Dec 2021
Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A
Role: Principal Investigator
Funding: BAXALTA US
Apr 2016 ACTIVE
PHASE 3, PROSPECTIVE, MULTICENTER OPEN LABEL STUDY TO INVESTIGATE SAFETY IMMUNOGENICITY AND HEMOSTATICE EFFICACY..
Role: Principal Investigator
Funding: BAXTER INTERNATIONAL
Nov 2015 – Nov 2020
A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
Role: Principal Investigator
Funding: PFIZER INC PHARMACEUTICALS
Dec 2014 – Dec 2017
Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via ASTRAZENECA
Oct 2014 – Jul 2019
30 DAY OPEN LABEL ACTIVE CONTROLLED RANDOMIZED STUDY OF THE SAFETY, EFFICACY AND THE PHARMACOKINETIC AND PHARMACODYNAMIC
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Oct 2014 – Oct 2017
30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Oct 2014 – Apr 2019
MULTICENTER, OPEN-LABEL, ACTIVE-CONTROLLED, RANDOMIZED STUDYTO EVALUATE THE EFFICACY AND SAFETY OF AN AGE AND BODY
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Oct 2014 – Oct 2017
Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Jul 2014 – Jul 2017
A PHASE 3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY OF BAX 855 (PEGYLATEDFULL-LENGTH RECOMBINANT FVIII) IN PREVIOUSLY TREATED PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
Role: Principal Investigator
Funding: IQVIA via BAXTER INTERNATIONAL
Jul 2014 – Jul 2017
A PHASE 3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS,EFFICACY,SAFETY…..
Role: Principal Investigator
Funding: IQVIA via BAXTER INTERNATIONAL
Apr 2014 – Apr 2017
Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism.
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Jan 2014 – Jan 2018
A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY OF EFFICACY AND SAFETY OF PEGYLATED RFVIII (BAX855) IN PREVIOUSLY TREATED .
Role: Principal Investigator
Funding: IQVIA via BAXALTA US
Jan 2014 – Jan 2017
A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX855) in Previously Treated Patients with Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures
Role: Principal Investigator
Funding: IQVIA via BAXALTA US
Dec 2013 – Dec 2019
A PHASE 3B CONTINUATION STUDY OF THE SAFETY AND EFFICACY OF PEGYLATED RECOMBINANT FACTOR VIII (PEG-RFVIII; BAX 855)
Role: Principal Investigator
Funding: BAXTER HEALTHCARE CORP
Dec 2013 – Dec 2019
Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding inPreviously Treated Patients with Severe Hemophilia A
Role: Principal Investigator
Funding: BAXTER HEALTHCARE CORP
Jun 2013 – May 2017
Southeast Region Comprehensive and Diagnostic Bleeding Disorders Treatment Center Program
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN

Education

Fellowship – Hematology and Oncology
2003 · Columbus Children's Hospital
Residency – Pediatrics
2000 · Children's Hospital Medical Center of Akron
Medical Degree
1997 · Northeastern Ohio University
Bachelors of Science
1993 · Kent State University

Contact Details

Phones:
Business:
(352) 273-9120
Emails:
Business:
twynn@ufl.edu
Addresses:
Business Mailing:
PO BOX 100298
GAINESVILLE FL 326100001
Business Street:
SHANDS CHILDREN'S HOSPITAL
GAINESVILLE FL 326100001